Treatment of obesity in older persons-A systematic review.
Cilla J HaywoodPriya SumithranPublished in: Obesity reviews : an official journal of the International Association for the Study of Obesity (2019)
The study aims to systematically review the available evidence regarding weight loss interventions (lifestyle, surgical, and pharmacological) for obesity in adults aged over 60 years. A search of prospective, randomized studies took place in January 2018, on Medline (Web of Science) and PubMed databases. Search terms included the following: elderly, obese, hypocaloric, pharmacotherapy, and bariatric surgery. Abstracts were screened for eligibility. A total of 256 publications regarding lifestyle interventions were identified; of these, 69 studies were eligible. As no eligible studies were identified for pharmacotherapy or bariatric surgery, the search was broadened to include non- randomized studies. Four pharmacotherapy and 66 surgery studies were included. Lifestyle intervention had similar weight loss efficacy in older compared with younger people, with positive effects on a number of relevant outcomes, including physical function and cardiovascular parameters. There was little data regarding obesity pharmacotherapy in older persons. The available data for bariatric surgery indicate comparable weight loss and resolution of type 2 diabetes, with similar or slightly higher complication rates in older compared with younger people. Older age alone should not be considered a contraindication to intensive lifestyle or surgical intervention for obesity. There are insufficient data to guide clinical decisions regarding obesity pharmacotherapy in older people.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- community dwelling
- physical activity
- obese patients
- gastric bypass
- middle aged
- case control
- glycemic control
- smoking cessation
- randomized controlled trial
- weight gain
- electronic health record
- metabolic syndrome
- big data
- double blind
- open label
- minimally invasive
- public health
- phase iii
- placebo controlled
- cardiovascular disease
- acute coronary syndrome
- machine learning
- study protocol
- insulin resistance
- atrial fibrillation
- single molecule
- replacement therapy
- artificial intelligence